Glucaric acid is a lipid of Fatty Acyls (FA) class. Glucaric acid is associated with abnormalities such as Consumption-archaic term for TB and furuncle. The involved functions are known as Oxidation, Mutation, Process, Cell Growth and Anabolism. Glucaric acid often locates in BL21, Clone and host. The associated genes with Glucaric acid are MIOX gene, ISYNA1 gene, Genome and Candidate Disease Gene. The related experimental models are Knock-out.
To understand associated biological information of Glucaric acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Glucaric acid is suspected in and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Glucaric acid
Lipid pathways are not clear in current pathway databases. We organized associated pathways with Glucaric acid through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Pathway name | Related literatures |
---|
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'Evolution-guided optimization of biosynthetic pathways.' (Raman S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Kriebel D et al. | Detection of occupational exposure to genotoxic agents with a urinary mutagen assay. | 1983 | Mutat. Res. | pmid:6835232 |
Scassellati-Sforzolini G et al. | In vivo studies on genotoxicity of pure and commercial linuron. | 1997 | Mutat. Res. | pmid:9186570 |
Auerbach M and Rodgers GM | Intravenous iron. | 2007 | N. Engl. J. Med. | pmid:17611217 |
McLean AE | Cancer and nutrition (review). | 1976 | Nahrung | pmid:781541 |
Gomollón F and Gisbert JP | IBD: Intravenous iron in IBD--what's the best preparation? | 2011 | Nat Rev Gastroenterol Hepatol | pmid:21788975 |
Dueber JE et al. | Synthetic protein scaffolds provide modular control over metabolic flux. | 2009 | Nat. Biotechnol. | pmid:19648908 |
DeLisa MP and Conrado RJ | Synthetic metabolic pipelines. | 2009 | Nat. Biotechnol. | pmid:19668178 |
Faber F et al. | Host-mediated sugar oxidation promotes post-antibiotic pathogen expansion. | 2016 | Nature | pmid:27309805 |
Fernández-Gallego J et al. | [Treatment with intravenous iron and ferritin level]. | 2010 | Nefrologia | pmid:20514109 |
Balázová E et al. | Antitumor activity of four polymer bound trans-1,2-diaminocyclohexaneplatinum(II)-4-carboxyphtalate complexes tested in different model systems. | 1986 | Neoplasma | pmid:3808121 |
Hrubisko M et al. | Drug resistance induction and cross-resistance studies with Pt-complexes. | 1984 | Neoplasma | pmid:6542968 |
Edwards JH | Clinical review of the newer intravenous iron therapy options. | 2003 | Nephrol Nurs J | pmid:12674953 |
Folkert VW | Intravenous iron therapy in chronic kidney disease and peritoneal dialysis patients. | 2003 | Nephrol Nurs J | pmid:14621635 |
Colfer M | Achieving optimal patient outcomes with intravenous iron. | 2003 | Nephrol Nurs J | pmid:14533524 |
Stoves J et al. | A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. | 2001 | Nephrol. Dial. Transplant. | pmid:11328902 |
Carlini RG et al. | Apoptotic stress pathway activation mediated by iron on endothelial cells in vitro. | 2006 | Nephrol. Dial. Transplant. | pmid:16957011 |
Schiesser D et al. | Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. | 2006 | Nephrol. Dial. Transplant. | pmid:16891647 |
Guz G et al. | Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. | 2006 | Nephrol. Dial. Transplant. | pmid:16762960 |
Chuang CL et al. | Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. | 2003 | Nephrol. Dial. Transplant. | pmid:12543894 |
Parkkinen J et al. | Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. | 2000 | Nephrol. Dial. Transplant. | pmid:11071973 |
Fell LH et al. | Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells. | 2016 | Nephrol. Dial. Transplant. | pmid:27190361 |
Silverberg D et al. | The use of androgens in anaemia resistant to erythropoietin and i.v. iron in patients with heart and renal failure. | 2004 | Nephrol. Dial. Transplant. | pmid:15031380 |
Airy M et al. | Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. | 2015 | Nephrol. Dial. Transplant. | pmid:26311216 |
Bhandari S et al. | A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. | 2015 | Nephrol. Dial. Transplant. | pmid:25925701 |
Onken JE et al. | Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. | 2014 | Nephrol. Dial. Transplant. | pmid:23963731 |
McMahon LP et al. | Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. | 2010 | Nephrol. Dial. Transplant. | pmid:19906658 |
Rottembourg J et al. | Do two intravenous iron sucrose preparations have the same efficacy? | 2011 | Nephrol. Dial. Transplant. | pmid:21355067 |
Wang S et al. | Chemical reactions of vitamin C with intravenous-iron formulations. | 2008 | Nephrol. Dial. Transplant. | pmid:17951305 |
al-Hawas F et al. | Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin. | 1997 | Nephrol. Dial. Transplant. | pmid:9430909 |
Sunder-Plassmann G and Hörl WH | Safety of intravenous injection of iron saccharate in haemodialysis patients. | 1996 | Nephrol. Dial. Transplant. | pmid:8918625 |
George P et al. | Coronary artery vasospasm with iron sucrose. | 2007 | Nephrol. Dial. Transplant. | pmid:17327282 |
Sunder-Plassmann G et al. | The dilemma of evaluating iron status in dialysis patients--limitations of available diagnostic procedures. | 1997 | Nephrol. Dial. Transplant. | pmid:9269632 |
Lim PS et al. | Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. | 1999 | Nephrol. Dial. Transplant. | pmid:10534512 |
Ranfaing E | [Treatments of the martial deficiencies: preparations available in France]. | 2006 | Nephrol. Ther. | pmid:17373280 |
Tiranathanagul K et al. | Oxidative stress from rapid versus slow intravenous iron replacement in haemodialysis patients. | 2004 | Nephrology (Carlton) | pmid:15363053 |
Wu CJ et al. | Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients. | 2010 | Nephrology (Carlton) | pmid:20377770 |
Garcia-Fernandez N et al. | Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. | 2010 | Nephrology (Carlton) | pmid:20470276 |
Ozdemir A et al. | Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemodialysis patients. | 2005 | Nephrology (Carlton) | pmid:16221090 |
Descombes E and Fellay G | Improved response to erythropoietin therapy with long-term continuous iron supplementation. | 2000 | Nephron | pmid:10657727 |
Silverberg DS et al. | Intravenous ferric saccharate as an iron supplement in dialysis patients. | 1996 | Nephron | pmid:8852489 |
Sheashaa H et al. | Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate. | 2005 | Nephron Clin Pract | pmid:15692217 |
Stefánsson BV et al. | Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. | 2011 | Nephron Clin Pract | pmid:21196770 |
Charytan C et al. | Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. | 2004 | Nephron Clin Pract | pmid:14988600 |
Frezza M et al. | Abnormal serum gamma-glutamyltranspeptidase in alcoholics. Clues to its explanation. | 1989 | Neth J Med | pmid:2563572 |
Ciuffi M et al. | Lipid peroxidation induced "in vivo" by iron-carbohydrate complex in the rat brain cortex. | 1991 | Neurochem. Res. | pmid:2052138 |
Koller WC et al. | Metabolism of glucurolactone to glucarate in Parkinson's disease. | 1992 | Neurology | pmid:1513472 |
de Wolff FA et al. | Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate. | 1982 | Neuropediatrics | pmid:6123089 |
Masaki H | [Metabolic pathway of D-glucaric acid synthesis from D-glucuronolactone in the skin. II. Identification of the intermediates in D-glucuronolactone D-glucaric acid metabolism]. | 1972 | Nihon Hifuka Gakkai Zasshi | pmid:4540858 |
Nasaki H | [Metabolic pathway of D-glucaric acid synthesis from D-glucuronolactone in the skin. 1. D-glucaric acid and D-glucuronolactone dehydrogenase activities in the human skin--feedback mechanism of beta-glucuronidase]. | 1972 | Nihon Hifuka Gakkai Zasshi | pmid:4540880 |
Ogi M et al. | [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients]. | 2004 | Nihon Jinzo Gakkai Shi | pmid:15645737 |